Inmazeb

Chemical Nameatoltivimab, maftivimab, and odesivimab
Dosage FormInjection (intravenous; atoltivimab mg/maftivimab mg/odesivimab mg per mL: 241.7 mg/ 241.7 mg/ 241.7 mg per 14.5 mL, 16.67 mg/16.67 mg/16.67 mg per mL)
Drug ClassMonoclonal antibodies
SystemBlood
CompanyRegeneron Pharmaceuticals
Approval Year2020

Indication

  • For the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Prescribing Information. 2020Regeneron Pharmaceuticals Inc., Tarrytown, NY
Document TitleYearSource
A randomized, controlled trial of ebola virus disease therapeutics. 2019The New England Journal of Medicine